Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
Tuesday, July 22, 2025Lantern Pharma Inca clinicalstage oncology company leveraging its proprietary RADR artificial intelligence AI platform to accelerate drug discovery today announced that the European Patent Office EPO has issued a notice of allowance for a composition...
George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US
Tuesday, July 22, 2025George Medicines a latestage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease has entered into an exclusive licensing and supply agreement with Azurity Pharmaceuticals
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
Saturday, July 19, 2025ARS Pharmaceuticals Inca biopharmaceutical company dedicated to empowering atrisk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis announced today that the United Kingdom UK
Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU)
Friday, July 18, 2025Cycle Pharmaceuticals announced the launch of HARLIKU the first and only FDAapproved treatment for reducing urinary homogentisic acid HGA in adult patients with alkaptonuria AKU
Sanofi completes acquisition of Blueprint Medicines
Friday, July 18, 2025Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation Blueprint adding to its portfolio a commercialized medicine a promising pipeline and the expertise of a company specializing in systemic mastocytosis
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
Thursday, July 17, 2025Oragenics Inc a biotechnology company developing intranasal therapeutics for brainrelated conditions today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions an industry leading
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
Wednesday, July 16, 2025Biocon Biologics Ltd BBL a fully integrated global biosimilars company and subsidiary of Biocon Ltd BSE code NSE BIOCON today announced that the US Food and Drug Administration FDA has approved Kirsty
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
Tuesday, July 15, 2025The Series B round saw strong participation from both existing and new investors demonstrating high industry confidence in Illimis Therapeutics vision and technology Eight existing investors including DSC Investment Woori Venture Partners Korea Devel...
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
Tuesday, July 15, 2025Merck known as MSD outside of the United States and Canada today announced the initiation of the EXPrESSIVE Phase clinical trials evaluating the safety and efficacy of MK an investigational oncemonthly
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
Friday, July 11, 2025Earendil Labs an AIempowered biotechnology company announced that it has completed cohort dosing in a phase trial for a novel antiTLA antibody HXN The phase study is designed to evaluate the safety
